用于预防和治疗血管疾病的药物引起的血脂异常。
Dyslipidemia induced by drugs used for the prevention and treatment of vascular diseases.
作者信息
Tziomalos Konstantinos, Athyros Vasilios G, Karagiannis Asterios, Mikhailidis Dimitri P
机构信息
Department of Clinical Biochemistry (Vascular Prevention Clinic) and Department of Surgery, Royal Free Campus, University College London Medical School, University College London (UCL), London, UK.
出版信息
Open Cardiovasc Med J. 2011;5:85-9. doi: 10.2174/1874192401105010085. Epub 2011 Feb 24.
Abstract
Dyslipidemia is a major vascular risk factor. Interestingly, several agents used for the prevention and treatment of vascular diseases have an adverse effect on the lipid profile. In addition, agents belonging to the same class (e.g. beta blockers) can have significantly different actions on lipid levels. We summarize the effects of drugs used for the prevention and treatment of vascular diseases on the lipid profile. These effects should be considered when selecting a specific agent, particularly in high-risk patients.
摘要
血脂异常是主要的血管危险因素。有趣的是，几种用于预防和治疗血管疾病的药物对血脂谱有不良影响。此外，属于同一类别的药物（如β受体阻滞剂）对血脂水平的作用可能有显著差异。我们总结了用于预防和治疗血管疾病的药物对血脂谱的影响。在选择特定药物时，尤其是在高危患者中，应考虑这些影响。
相似文献
1
Dyslipidemia induced by drugs used for the prevention and treatment of vascular diseases.用于预防和治疗血管疾病的药物引起的血脂异常。
Open Cardiovasc Med J. 2011;5:85-9. doi: 10.2174/1874192401105010085. Epub 2011 Feb 24.
2
Effect of hypertension and its treatment on lipid, lipoprotein(a), fibrinogen, and bilirubin levels in patients referred for dyslipidemia.高血压及其治疗对血脂异常患者血脂、脂蛋白（a）、纤维蛋白原和胆红素水平的影响。
Am J Hypertens. 1999 Jul;12(7):673-81. doi: 10.1016/s0895-7061(99)00049-7.
3
Fenofibrate: a review of its lipid-modifying effects in dyslipidemia and its vascular effects in type 2 diabetes mellitus.非诺贝特：在血脂异常中的调脂作用及其在 2 型糖尿病中的血管作用评价。
Am J Cardiovasc Drugs. 2011 Aug 1;11(4):227-47. doi: 10.2165/11207690-000000000-00000.
4
Safety of drugs commonly used to treat hypertension, dyslipidemia, and type 2 diabetes (the metabolic syndrome): part 1.
Diabetes Technol Ther. 2000 Spring;2(1):101-10. doi: 10.1089/152091599316801.
5
6
Niacin as a component of combination therapy for dyslipidemia.烟酸作为血脂异常联合治疗的一种成分。
Mayo Clin Proc. 2003 Jun;78(6):735-42. doi: 10.4065/78.6.735.
7
Nonfasting Lipid Profile May Suffice to Manage Dyslipidemia.非空腹血脂谱可能足以用于管理血脂异常。
Indian J Psychol Med. 2020 Apr 25;42(3):316-317. doi: 10.4103/IJPSYM.IJPSYM_178_20. eCollection 2020 May-Jun.
8
[Antihypertensive therapy and lipid metabolism].[抗高血压治疗与脂质代谢]
Klin Wochenschr. 1984 Mar 1;62(5):193-202. doi: 10.1007/BF01721044.
9
Cardiovascular co-medication among users of antiobesity drugs: a population-based study.抗肥胖药物使用者的心血管联合用药：一项基于人群的研究。
Pharm World Sci. 2010 Dec;32(6):752-8. doi: 10.1007/s11096-010-9432-7. Epub 2010 Aug 29.
10
Atherogenic dyslipidemia: prevalence and management in lipid clinics.
Rev Clin Esp (Barc). 2014 Dec;214(9):491-8. doi: 10.1016/j.rce.2014.06.001. Epub 2014 Jul 9.
引用本文的文献
1
Medication Induced Dyslipidemia in Children.儿童药物性血脂异常
Curr Atheroscler Rep. 2025 Apr 21;27(1):52. doi: 10.1007/s11883-025-01297-9.
2
Therapeutical Approach to Arterial Hypertension - Current State of the Art.动脉高血压的治疗方法——最新技术现状。
Curr Med Chem. 2024;31(29):4602-4620. doi: 10.2174/0109298673274823231220063652.
3
Antihypertensives associated adverse events: a review of mechanisms and pharmacogenomic biomarkers available evidence in multi-ethnic populations.抗高血压药物相关不良事件：多民族人群中机制及药物基因组学生物标志物的现有证据综述
Front Pharmacol. 2023 Dec 1;14:1286494. doi: 10.3389/fphar.2023.1286494. eCollection 2023.
4
Haematological Drugs Affecting Lipid Metabolism and Vascular Health.影响脂质代谢和血管健康的血液学药物
Biomedicines. 2022 Aug 10;10(8):1935. doi: 10.3390/biomedicines10081935.
5
Common medications used by patients with type 2 diabetes mellitus: what are their effects on the lipid profile?2型糖尿病患者常用药物：它们对血脂谱有何影响？
Cardiovasc Diabetol. 2016 Jul 14;15:95. doi: 10.1186/s12933-016-0412-7.
本文引用的文献
1
Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial.罗格列酮用于2型糖尿病口服联合治疗的心血管结局评估（RECORD）：一项多中心、随机、开放标签试验
Lancet. 2009 Jun 20;373(9681):2125-35. doi: 10.1016/S0140-6736(09)60953-3. Epub 2009 Jun 6.
2
Effects of losartan compared with atenolol on lipids in patients with hypertension and left ventricular hypertrophy: the Losartan Intervention For Endpoint reduction in hypertension study.氯沙坦与阿替洛尔对高血压伴左心室肥厚患者血脂的影响：氯沙坦干预降低高血压终点事件研究
J Hypertens. 2009 Mar;27(3):567-74. doi: 10.1097/HJH.0b013e32831daf96.
3
How safe is the use of thiazolidinediones in clinical practice?噻唑烷二酮类药物在临床实践中的使用安全性如何？
Expert Opin Drug Saf. 2009 Jan;8(1):15-32. doi: 10.1517/14740330802597821.
4
Effect of rimonabant on the high-triglyceride/ low-HDL-cholesterol dyslipidemia, intraabdominal adiposity, and liver fat: the ADAGIO-Lipids trial.利莫那班对高甘油三酯/低高密度脂蛋白胆固醇血脂异常、腹内脂肪堆积及肝脏脂肪的影响：ADAGIO-脂质试验
Arterioscler Thromb Vasc Biol. 2009 Mar;29(3):416-23. doi: 10.1161/ATVBAHA.108.176362. Epub 2008 Dec 26.
5
Colesevelam improves glycemic control and lipid management in inadequately controlled type 2 diabetes mellitus.
Nat Clin Pract Endocrinol Metab. 2009 Jan;5(1):16-7. doi: 10.1038/ncpendmet1021. Epub 2008 Nov 18.
6
Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes.2 型糖尿病患者高血糖的医学管理：起始和调整治疗的共识算法：美国糖尿病协会和欧洲糖尿病研究协会的共识声明。
Diabetes Care. 2009 Jan;32(1):193-203. doi: 10.2337/dc08-9025. Epub 2008 Oct 22.
7
Omega-3 fatty acids: how can they be used in secondary prevention?欧米伽-3脂肪酸：它们如何用于二级预防？
Curr Atheroscler Rep. 2008 Dec;10(6):510-7. doi: 10.1007/s11883-008-0079-y.
8
The differential effects of thiazolidindiones on atherogenic dyslipidemia in type 2 diabetes: what is the clinical significance?噻唑烷二酮类药物对2型糖尿病患者致动脉粥样硬化性血脂异常的不同作用：临床意义何在？
Expert Opin Pharmacother. 2008 Sep;9(13):2295-303. doi: 10.1517/14656566.9.13.2295.
9
Efficacy and safety of colesevelam in patients with type 2 diabetes mellitus and inadequate glycemic control receiving insulin-based therapy.考来维仑在接受胰岛素治疗但血糖控制不佳的2型糖尿病患者中的疗效与安全性。
Arch Intern Med. 2008 Jul 28;168(14):1531-40. doi: 10.1001/archinte.168.14.1531.
10
Pramlintide, the synthetic analogue of amylin: physiology, pathophysiology, and effects on glycemic control, body weight, and selected biomarkers of vascular risk.普兰林肽，胰淀素的合成类似物：生理学、病理生理学以及对血糖控制、体重和血管风险选定生物标志物的影响
Vasc Health Risk Manag. 2008;4(2):355-62. doi: 10.2147/vhrm.s1978.
Zotero 插件